CAROLINE LUKANO: Open Payments
NPI 1023498466 · COLUMBUS, GA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$572 in 29 payments from 12 companies in 2025. Trend: 2023 $1,620 · 2024 $1,074 · 2025 $572
Food & beverage: $572
| Company | Payments | Amount |
|---|---|---|
| Neurocrine BioSciences, Inc. | 6 | $142 |
| E.R. Squibb & Sons, L.L.C. | 4 | $77 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 3 | $71 |
| Vanda Pharmaceuticals Inc. | 3 | $60 |
| Otsuka America Pharmaceutical, Inc. | 3 | $54 |
| Janssen Pharmaceuticals, Inc | 3 | $52 |
| Alkermes, Inc. | 2 | $36 |
| Lundbeck LLC | 1 | $17 |
| Noven Therapeutics, LLC | 1 | $17 |
| Luye Pharma (USA) Ltd. | 1 | $16 |
Products named: INGREZZA, COBENFY, CAPLYTA, FANAPT, ABILIFY MAINTENA, ARISTADA, SPRAVATO, INVEGA SUSTENNA.
Industry payments across GA — which companies pay providers there.
